799
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?

&
Pages 1277-1280 | Published online: 16 May 2013

Bibliography

  • Schmid H. Peginesatide for the treatment of renal disease-induced anemia. Exp Opin Pharmacother 2013;14:937-48
  • Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11
  • Macdougall IC, Provenzano R, Sharma A, et al. PEARL Study Groups. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32
  • Fishbane S, Schiller B, Locatelli F, et al. EMERALD Study Groups. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19
  • Available from: http://omontys.com/ [Last viewed on 26 February 2013]
  • Available from: http://medicalxpress.com/news/2013-02-fda-omontys.html [Viewed on 26 February 2013]
  • Fineberg SE, Galloway JA, Fineberg NS, et al. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983;25:465-9
  • Matsuda F, Torii Y, Enomoto H, et al. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C. J Viral Hepat 2012;19:694-703
  • Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012;18:1775-81
  • Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11
  • Woodburn KW, Schatz PJ, Fong KL, Beaumier P. Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys. Int J Immunopathol Pharmacol 2010;23(1):121-9
  • Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361:1848-55
  • Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures–2012. Am J Health Syst Pharm 2012;69:405-21
  • Woodburn KW, Wilson SD, Fong KL, et al. Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 2008;93:1376-9
  • Siscovick DS, Sotoodehnia N, Rea TD, et al. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord 2010;11:53-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.